NCI

Combining inhibitors of the BMP signaling pathway with standard chemotherapy drugs may overcome drug resistance in ovarian cancer. Read More

Leora Horn, M.D., M.Sc., associate professor of Medicine and clinical director of the Thoracic Oncology Program at Vanderbilt-Ingram Cancer Center (VICC), has received a 2015 Cancer Clinical Investigator Team Leadership Award (CCITLA) from the National Cancer Institute (NCI). Read More

A signaling protein that is essential for recovery from acute kidney injury works by increasing the population of tissue-repairing immune cells. Read More

Vanderbilt investigators have generated a “parts list” for the molecular machinery that duplicates DNA each time a cell divides. The research has implications for cancer therapies that target components of this machinery. Read More

Understanding factors, such as the receptor TLR9, that detect and defend against pathogens may lead to therapeutic approaches that promote an effective immune response to treat infections. Read More

The glutamine transporter protein appears to contribute to the survival of lung cancer cells, suggesting it may be a useful diagnostic biomarker and target for therapies. Read More

New findings add to the understanding of how the enzyme COX-2 works, which is critical to the development of COX-2-targeted anti-inflammatory drugs. Read More

Understanding how signaling molecules are transported within and out of the cell may help to uncover the causes of certain cancers. Read More

Vanderbilt investigators have discovered how mammals, including humans, produce the painkiller morphine. Read More

Drugs that target DNA damage improve ovarian cancer cell response to platinum chemotherapies, suggesting new therapeutic opportunities. Read More

Vanderbilt scientists have discovered a new molecular mechanism that promotes stomach cancer development, findings that could provide new opportunities for treatment. Read More

The rigidity of the bone extracellular matrix increases the ability of tumor cells to destroy bone, suggesting new targets for anticancer drug development. Read More

Vanderbilt investigators have developed a new algorithm to understand the networks of signaling molecules that control drug action. Read More

A new mouse model demonstrates that the Hhex gene – which is linked to blood cancers – is critical for normal blood cell production. Read More

Inhibitors of the enzyme phospholipase D1 suppress the replication of HIV-1, Vanderbilt investigators have discovered. Read More

The proteins that control entry and exit from the cell nucleus influence aging, Vanderbilt researchers have discovered. Read More

Mechanical stress appears to be a critical factor in activating normal tissue-associated fibroblasts to generate cancer-associated fibroblasts. Read More

A specific gene expression profile represents a novel, biologically relevant “signature” for identifying colon cancers with high risk of metastatic recurrence, Vanderbilt researchers have found. Read More

A protein that degrades the “matrix” between cells participates in the development of lung metastases from primary breast cancer in mouse models and may be a good target for breast cancer treatment. Read More

Vanderbilt investigators have used a computational biology approach to uncover new cancer drivers and biomarkers of anticancer drug response. Read More